Printer Friendly

Roche's Roactemra rejected by NICE.

M2 EQUITYBITES-December 6, 2017-Roche's Roactemra rejected by NICE

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Roche's drug Roactemra (tocilizumab) has been rejected by the NHS. According to Pharma File on Wednesday, the drug was turned down by the National Institute for Health and Care Excellence (NICE).

The cost watchdog's ruling means it is unlikely that patients with giant cell arteritis will have access to the treatment any time soon. The appraisal committee stated that its verdict came as a result of "substantial uncertainties" in the evidence centring on how long patients would have to take the treatment and what the long-term benefits are.

Giant cell arteritis is a kind of vasculitis that causes inflammation of blood vessels. It is usually treated using a high dose of corticosteroids, which is gradually tapered over time. However, the conventional treatment has been known to cause skin problems and weight gain. Meanwhile, long-term use has been linked to diabetes and osteoporosis.

Clinical data does demonstrate that after having Roactemra plus corticosteroids for one year, more people were able to sustain a remission and require smaller doses of corticosteroids compared with people having corticosteroids alone.

Yet NICE said that the cost-effectiveness estimate for the drug was calculated to be at least [pounds sterling]65,800 per quality adjusted life year gained. That is substantially more than what is usually considered value for money for the NHS.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Dec 6, 2017
Words:243
Previous Article:Novaliq has NovaTears+Omega-3 treatment approved in Europe.
Next Article:Butterfield Bank names non-executive director.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters